Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Heterobivalent agents targeting PSMA and integrin-αvβ3.

Shallal HM, Minn I, Banerjee SR, Lisok A, Mease RC, Pomper MG.

Bioconjug Chem. 2014 Feb 19;25(2):393-405. doi: 10.1021/bc4005377. Epub 2014 Jan 22.

2.

A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.

Chatalic KL, Veldhoven-Zweistra J, Bolkestein M, Hoeben S, Koning GA, Boerman OC, de Jong M, van Weerden WM.

J Nucl Med. 2015 Jul;56(7):1094-9. doi: 10.2967/jnumed.115.156729. Epub 2015 May 14.

3.

Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.

Subedi M, Minn I, Chen J, Kim Y, Ok K, Jung YW, Pomper MG, Byun Y.

Eur J Med Chem. 2016 Aug 8;118:208-218. doi: 10.1016/j.ejmech.2016.04.033. Epub 2016 Apr 14.

4.

Development of a complementary PET/MR dual-modal imaging probe for targeting prostate-specific membrane antigen (PSMA).

Moon SH, Yang BY, Kim YJ, Hong MK, Lee YS, Lee DS, Chung JK, Jeong JM.

Nanomedicine. 2016 May;12(4):871-879. doi: 10.1016/j.nano.2015.12.368. Epub 2015 Dec 29.

5.

In Vivo Molecular MRI Imaging of Prostate Cancer by Targeting PSMA with Polypeptide-Labeled Superparamagnetic Iron Oxide Nanoparticles.

Zhu Y, Sun Y, Chen Y, Liu W, Jiang J, Guan W, Zhang Z, Duan Y.

Int J Mol Sci. 2015 Apr 28;16(5):9573-87. doi: 10.3390/ijms16059573.

6.

PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer.

Xiang B, Dong DW, Shi NQ, Gao W, Yang ZZ, Cui Y, Cao DY, Qi XR.

Biomaterials. 2013 Sep;34(28):6976-91. doi: 10.1016/j.biomaterials.2013.05.055. Epub 2013 Jun 15.

PMID:
23777916
7.

Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer.

Eder M, Schäfer M, Bauder-Wüst U, Haberkorn U, Eisenhut M, Kopka K.

Prostate. 2014 May;74(6):659-68. doi: 10.1002/pros.22784. Epub 2014 Jan 25.

8.

A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.

Ganguly T, Dannoon S, Hopkins MR, Murphy S, Cahaya H, Blecha JE, Jivan S, Drake CR, Barinka C, Jones EF, VanBrocklin HF, Berkman CE.

Nucl Med Biol. 2015 Oct;42(10):780-7. doi: 10.1016/j.nucmedbio.2015.06.003. Epub 2015 Jun 9.

9.

Selection and characterization of Anticalins targeting human prostate-specific membrane antigen (PSMA).

Barinka C, Ptacek J, Richter A, Novakova Z, Morath V, Skerra A.

Protein Eng Des Sel. 2016 Mar;29(3):105-15. doi: 10.1093/protein/gzv065. Epub 2016 Jan 21.

PMID:
26802163
10.

PSMA-targeted stably linked "dendrimer-glutamate urea-methotrexate" as a prostate cancer therapeutic.

Huang B, Otis J, Joice M, Kotlyar A, Thomas TP.

Biomacromolecules. 2014 Mar 10;15(3):915-23. doi: 10.1021/bm401777w. Epub 2014 Feb 10.

PMID:
24392665
11.

Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer.

Bandekar A, Zhu C, Jindal R, Bruchertseifer F, Morgenstern A, Sofou S.

J Nucl Med. 2014 Jan;55(1):107-14. doi: 10.2967/jnumed.113.125476. Epub 2013 Dec 12.

12.

In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.

Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH.

Cancer Res. 2000 Sep 15;60(18):5237-43.

13.

Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.

Benešová M, Schäfer M, Bauder-Wüst U, Afshar-Oromieh A, Kratochwil C, Mier W, Haberkorn U, Kopka K, Eder M.

J Nucl Med. 2015 Jun;56(6):914-20. doi: 10.2967/jnumed.114.147413. Epub 2015 Apr 16.

14.

Prostate-specific membrane antigen as a target for cancer imaging and therapy.

Kiess AP, Banerjee SR, Mease RC, Rowe SP, Rao A, Foss CA, Chen Y, Yang X, Cho SY, Nimmagadda S, Pomper MG.

Q J Nucl Med Mol Imaging. 2015 Sep;59(3):241-68. Epub 2015 Jul 24. Review.

15.

Development of targeted near-infrared imaging agents for prostate cancer.

Wang X, Huang SS, Heston WD, Guo H, Wang BC, Basilion JP.

Mol Cancer Ther. 2014 Nov;13(11):2595-606. doi: 10.1158/1535-7163.MCT-14-0422. Epub 2014 Sep 19.

16.

A low molecular weight PSMA-based fluorescent imaging agent for cancer.

Chen Y, Dhara S, Banerjee SR, Byun Y, Pullambhatla M, Mease RC, Pomper MG.

Biochem Biophys Res Commun. 2009 Dec 18;390(3):624-9. doi: 10.1016/j.bbrc.2009.10.017. Epub 2009 Oct 8.

17.

Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.

Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L.

J Nucl Med. 2015 Aug;56(8):1185-90. doi: 10.2967/jnumed.115.160382. Epub 2015 Jun 25.

18.

Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.

Bandari RP, Jiang Z, Reynolds TS, Bernskoetter NE, Szczodroski AF, Bassuner KJ, Kirkpatrick DL, Rold TL, Sieckman GL, Hoffman TJ, Connors JP, Smith CJ.

Nucl Med Biol. 2014 Apr;41(4):355-63. doi: 10.1016/j.nucmedbio.2014.01.001. Epub 2014 Jan 10.

19.

Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase.

Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ.

Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):5981-6. Epub 2005 Apr 18.

20.

Supplemental Content

Support Center